Here’s a bold statement: Malaysia has just unlocked a staggering RM1 billion in savings, and it’s all thanks to a shift in how the government buys its medicines. But here’s where it gets controversial—Prime Minister Anwar Ibrahim is challenging the long-held belief that expensive drugs from the US and Europe are the only way to ensure quality healthcare. At the inauguration of a new hospital block in Seberang Jaya on January 24, 2026, Anwar revealed that the government’s decision to prioritize generic drugs over pricier originator medicines has saved the country nearly RM1 billion in just two years.
Anwar didn’t hold back, stating, ‘We’ve wasted tens of billions of ringgit chasing the ‘best’ drugs from the US, where a single pill can cost RM100, when we could get the same treatment for RM10 from countries like India, Turkey, Brazil, or China—as long as they meet our medical standards.’ He emphasized that Malaysia should no longer take pride in relying on expensive Western medications, calling it an ‘outdated mentality.’
And this is the part most people miss—the shift to generic drugs isn’t just about cost savings; it’s about rethinking how we approach healthcare affordability without compromising quality. Health Minister Dzulkefly Ahmad reinforced this at a press conference, stating that generic drugs are just as safe and effective as their branded counterparts. He noted that the ‘generic-first policy’ has already saved over RM900 million in the past two years, with more savings expected.
But the conversation doesn’t stop at medicines. Anwar, also the finance minister, took aim at the snail-paced construction of public health infrastructure. He questioned why hospital projects, like the Seberang Jaya building that took nearly a decade to complete, are plagued by delays. ‘We need to learn from these experiences,’ he urged, calling for faster land approvals and better contractor performance.
Dzulkefly added that he and Works Minister Alexander Nanta Linggi are reviewing ‘sick’ projects nationwide, with some hospital constructions in Sabah and Sarawak delayed by up to a decade. ‘People can’t wait 5 to 10 years for these projects,’ he stressed, urging contractors to deliver on time.
Here’s a thought-provoking question for you: Is Malaysia’s shift to generic drugs a smart financial move, or does it risk undermining the perceived prestige of Western medicines? And how can we ensure public health projects are completed without unnecessary delays? Share your thoughts in the comments—let’s spark a conversation!
